Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Everest Group enters its October 28 earnings date with short interest climbing, analyst targets drifting lower, and the stock lagging its reinsurance peers over the past month, a setup that frames the Q3 print as a genuine test of the bull case.
Short sellers have been quietly adding pressure over the past month. Short interest as a percentage of the free float has risen from roughly 3.7% to 4.2%, a gain of about 11% in shares borrowed over 30 days, with the sharpest acceleration coming in the past week at just over 6%. That is not extreme by any measure, and the borrow market remains very loose: availability is running at 2,282%, meaning there are more than 22 shares available to lend for every one currently borrowed. Borrowing costs have edged higher, up about 14% on the week to 0.57%, but that still qualifies as low in absolute terms. The cost and availability picture rules out any squeeze dynamic. What the trend does tell you is that positioning has turned incrementally more bearish heading into the print. The ORTEX short score has also ticked up to 42 from around 41 earlier in the week, though it remains well below the elevated range it touched in mid-September when shares short peaked near 2 million. Options are a mild counterpoint: the put/call ratio of 0.38 is above its 20-day average of 0.29 by less than one standard deviation, suggesting some light defensive positioning without a pronounced rush to hedge.
The Street is broadly neutral but fragmented on price target. Most coverage sits at Neutral or equivalent, with the mean target around $411, implying about 12% upside from the current $366.84. Mizuho lowered its target this week from $416 to $398, maintaining its Neutral rating, a small but notable trim in the days before earnings. RBC Capital initiated with an Outperform and a $455 target in late September, one of the more constructive data points in recent weeks. The bull case rests on improving casualty and property reinsurance pricing, with management's loss ratio remediation expected to translate into better underwriting margins. Bears counter that social inflation remains a live threat to reserve adequacy, and that the stock has struggled to keep pace with the equal-weighted S&P 500. Valuation sits at a price-to-book of 0.80 and a trailing PE of 6.3, which looks cheap in isolation. EV/EBIT ranks in the 73rd percentile against the broader universe, and dividend score sits at 80, though the dividend data in the ORTEX records runs through mid-2022 and should not be treated as current. On EPS momentum, the 30-day rank is a healthy 74, suggesting estimates have been rising recently even as the 12-month forward growth rank of 36 points to anaemic near-term growth expectations.
Wikipedia attention for Everest Group spiked in late September, with a z-score of 2.86 against its own 90-day history, placing it in elevated retail-attention territory. That kind of spike often accompanies a specific news catalyst or broader sector rotation; in this case it roughly coincided with the RBC initiation and a period of heightened reinsurance sector coverage tied to hurricane season commentary. It is a retail-attention signal, not a revenue indicator, but it does confirm the stock has been getting more eyeballs than usual heading into the quarter.
Peer context sharpens the picture. On the week, EG is down 0.5%, while close peers ACGL and RNR are nearly flat, CB and AFG are marginally positive, and HG is up nearly 3%. That underperformance is modest but consistent with the month-long drift: the stock is off 3.7% over 30 days while most of its correlated peers have held ground. Institutional ownership is concentrated but stable, with BlackRock above 8% and the Vanguard entities together near 13%. None of the 13D/G filings on the register carry activist intent; all are passive 13G holders, with the most recent Norges Bank filing from May 2026 showing a 5.2% stake. Stakes are as last disclosed and holders may have moved since.
The October 28 print is the natural focal point: the last two earnings releases both produced single-day falls of roughly 5% and further declines over five days, so the market has been conditioning itself to expect disappointment from this name. Whether that reaction pattern continues or breaks is what makes the next three weeks worth watching closely.
See the live data behind this article on ORTEX.
Open EG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.